CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:miR-34a promotes the immunosuppressive function of multiple myeloma-associated macrophages by dampening the TLR-9 signaling.
miR-34a promotes the immunosuppressive function of multiple myeloma-associated macrophages by dampening the TLR-9 signaling.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现提示,靶向巨噬细胞 miR-34a/TLR9 轴可能减轻 MM 患者中与 CAR-T 疗法相关的免疫抑制。
多发性骨髓瘤(MM)采用免疫疗法,尤其是CAR-T(CAR-T)细胞疗法,已取得有前景的疗效。然而,部分 MM 患者对 CAR-T 治疗无反应,其原因仍不明确。本研究旨在调查 miR-34a 对 MM 患者来源巨噬细胞免疫抑制性极化的影响。
检测来自健康个体及 MM 患者的巨噬细胞中 miR-34a 和 Toll 样受体 9(TLR9)的水平。采用 ELISA 分析巨噬细胞样本的细胞因子谱,并开展共培养实验,评估 MM 相关巨噬细胞对 CAR-T 细胞的免疫调节影响。
MM 患者血液样本中巨噬细胞和 CD4+ T 淋巴细胞活化受到抑制。MM 相关巨噬细胞中过表达 miR-34a 会降低 TLR9 表达并损害炎症性极化。在共培养系统及动物模型中,MM 相关巨噬细胞以 miR-34a 依赖方式抑制 CAR-T 细胞活性及其杀伤肿瘤的作用。
研究结果提示,靶向巨噬细胞 miR-34a/TLR9 轴有望减轻 MM 患者 CAR-T 治疗相关免疫抑制。
Promising outcomes have been observed in multiple myeloma (MM) with the use of immunotherapies, specifically chimeric antigen receptor T (CAR-T) cell therapy. However, a portion of MM patients do not respond to CAR-T therapy, and the reasons for this lack of response remain unclear. The objective of this study was to investigate the impact of miR-34a on the immunosuppressive polarization of macrophages obtained from MM patients.
The levels of miR-34a and TLR9 (Toll-like receptor 9) were examined in macrophages obtained from both healthy individuals and patients with MM. ELISA was employed to investigate the cytokine profiles of the macrophage samples. Co-culture experiments were conducted to evaluate the immunomodulatory impact of MM-associated macrophages on CAR-T cells.
There was an observed suppressed activation of macrophages and CD4 + T lymphocytes in the blood samples of MM patients. Overexpression of miR-34a in MM-associated macrophages dampened the TLR9 expression and impaired the inflammatory polarization. In both the co-culture system and an animal model, MM-associated macrophages suppressed the activity and tumoricidal effect of CAR-T cells in a miR-34a-dependent manner.
The findings imply that targeting the macrophage miR-34a/TLR9 axis could potentially alleviate the immunosuppression associated with CAR-T therapy in MM patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。